OSE Immunotherapeutics Appoints Thomas Gidoin as
Chief Financial Officer

NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN:
FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief
Financial Officer. Thomas joins the Executive Committee, bringing over 15 years of deep
international expertise in capital markets, financial strategy, and governance to the company.

Thomas Gidoin is an experienced biopharma finance executive with a strong track record in strategic
financial leadership, both in private and public companies. Prior to joining OSE Immunotherapeutics,
he served as Chief Financial Officer at Advesya, a privately held Franco-Swiss clinical-stage biotech
company in oncology and autoimmune diseases, after having spent 8 years as CFO of GenSight
Biologics, a Euronext-listed French biopharma company developing gene therapies for
neurodegenerative retinal diseases, where he led the company’s financing strategy from the Series B
to the IPO on Euronext Paris and a number of follow-on transactions and structured financings.
Previously, Thomas was Vice President of Finance at DBV Technologies, where he led the Corporate
Finance team and contributed to public offerings and private placements, including the dual listing of
the company on the US NASDAQ. Prior to this, Thomas served as Northern Europe Business Controller
at PregLem in London, held several positions at Ipsen, including UK Operations Controller in London
and Senior Financial Analyst in the Global Operations division in Paris. He started his career in audit at
Ernst & Young in Paris.
He holds master’s degrees in international finance from ESGF Paris and in international management
from NEOMA Business School.
Thomas succeeds Anne-Laure Autret-Cornet, marking a new phase in the company’s financial
leadership.
Nicolas Poirier, Chief Executive Officer, OSE Immunotherapeutics, commented:
“Thomas joins OSE Immunotherapeutics with deep experience in biotech capital markets financing and
strategic financial planning. He has a clear understanding of what it takes to support innovation
through disciplined execution and rigorous cash management. His arrival comes at a time when
financial leadership is key to advancing our two late-stage assets and continuing to leverage our
research platform. His expertise will further reinforce the management team to prepare the next phase
of growth with clarity and focus.”
Thomas Gidoin, Chief Financial Officer, OSE Immunotherapeutics, said:
“I am thrilled to join OSE Immunotherapeutics at such a pivotal moment in its journey. With two late-
stage assets in oncology and inflammation, boosted by a highly innovative research platform, the
company is well positioned to create meaningful long-term value through clear multiple short-term
inflexion points. I look forward to working closely with the leadership team to help unlock the full
potential of OSE’s innovative pipeline.”




1
ABOUT OSE IMMUNOTHERAPEUTICS
OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology
(IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner
with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the
market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between
Nantes and Paris and is quoted on Euronext.

Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-
immuno.com. Click and follow us on LinkedIn



Contacts
Fiona Olivier Contact Media France: Contact Media US:
fiona.olivier@ose-immuno.com FP2COM RooneyPartners LLC
Florence Portejoie Kate Barrette
Sylvie Détry fportejoie@fp2com.fr kbarrette@rooneypartners.com
sylvie.detry@ose-immuno.com +33 6 07 768 283 +1 212 223 0561


Forward-looking statements
This press release contains express or implied information and statements that might be deemed forward-looking
information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based upon certain assumptions and assessments made
by OSE Immunotherapeutics’ management considering its experience and its perception of historical trends, current
economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as “expect”,
“anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import.
Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are
reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such
expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally
beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially
from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or
identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance. This press release includes only summary information and should be read with the OSE
Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial
report for the fiscal year 2024, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law,
OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or
revise the forward-looking information or statements.




2